Latest Content

Tagrisso Could Become Standard of Care for Some With EGFR+ NSCLC

June 2nd 2024, 12:00pm

By Chris Ryan

Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer.

Lymphadenectomy Didn’t Improve Progression, Survival in Ovarian Cancer

June 2nd 2024, 12:00pm

By Ariana Pelosci

Article

Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer.

Palliative Care via Telehealth Similarly Beneficial to Quality of Life in Lung Cancer

June 2nd 2024, 12:00pm

By Alex Biese

Article

Researchers found telehealth care to deliver comparable quality-of-life benefits versus in-person visits among patients with advanced non-small cell lung cancer.

Posttreatment Imfinzi Sets New Standard for Small Cell Lung Cancer

June 2nd 2024, 12:00pm

By Kristi Rosa

Article

For the first time in decades, a new regimen — consolidation Imfinzi after chemoradiation — improved outcomes in patients with limited-stage small cell lung cancer.

Rybrevant Plus Leclaza Has ‘Very Potent Activity’ in Lung Cancer Subset

June 1st 2024, 9:02pm

By Brielle Benyon

Video

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma

June 1st 2024, 5:00pm

By Gina Mauro

Article

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

Rybrevant Plus Leclaza May Be New Standard for EGFR-Mutant Lung Cancer

June 1st 2024, 3:00pm

By Brielle Benyon

Article

Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.

Adcetris Regimen Outperforms Intense Chemo in Classical Hodgkin Lymphoma

June 1st 2024, 12:00pm

By Brielle Benyon

Article

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.

The Miracle Workers of Cancer

May 31st 2024, 7:00pm

By John Smelcer, PhD, CAGS

Article

When a group of people told me my non-Hodgkin lymphoma cure was a miracle, I realized it was only made possible because of health care professionals.

Lorbrena Shows Longest Progression-Free Survival in Advanced NSCLC

May 31st 2024, 4:32pm

By Megan Hollasch

Article

Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.

Bill Walton Dies, Ancient Skull Shows Evidence of Cancer Surgery and More

May 31st 2024, 3:00pm

By Ashley Chan

Article

From NBA Hall of Famer Bill Walton dying from cancer to an ancient skull showing evidence of early cancer treatments, here’s what’s happening in the oncology space this week.